Chelation is Much More Effective than New Drug to Prevent CV Death for Diabetics

The new drug, empaliflozin, reduces the risk for future cardiac events, including premature death by 14% when added to conventional care.  This was in the front-page article of Family Practice News in October.  However, the TACT study of chelation produced a reduction of the same end points by about 50%.  Chelation also reduces the toxic metal load for patients, which might lessen the risk of cancer and other diseases.  If you are a diabetic, or even a pre-diabetic, I urge you to consider chelation.  Without chelation, having diabetes shortens the lifespan by 5-7 years.  Nothing works better.

See Family Practice News, October 15, 2015, p. 1.

Celebration of HealthAssociation website